New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC

▤ Summary

Ipsen announced new late-breaking data for IQIRVO at the EASL congress. The results reinforce the drug’s impact on alkaline phosphatase reduction, fatigue improvement, and pruritus relief in patients with primary biliary cholangitis. The company highlighted findings from the ELATIVE Phase III trial, a U.S. real-world analysis, and the ELFINITY Phase IV study. Ipsen says the data strengthen the evidence base for IQIRVO as a second-line PBC treatment with a favorable tolerability profile.

▦ Linked Companies